Antibiotic therapy in community-acquired pneumonia and the role of the hospital pharmacist

American Journal of Managed Care

Volumn 5, Issue 9 SUPPL., 1999, Pages

  Huber, Stephen L ^a   Wood, Jim G ^b   Weston, Jaye S ^c   Lomaestro, Ben M ^d   Timm, Edward G ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c EAST TEXAS MEDICAL CENTER   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE TYPE A; HOSPITAL PHARMACY; HUMAN; LEGIONELLA; MYCOPLASMA; PHARMACIST; PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0032782214     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Schentag JJ. The pharmacoeconomics of treating hospital-acquired pneumonia: Developing a rational strategy. Pharmaguide to Hosp Med 1997;10:1-4, 9-12.
2. Garrelts JC, Herrington AM. Cost-effective treatment of lower respiratory tract infections. Pharmacoeconomics 1996;10:36-58.
3. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618-1624.
4. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Guidelines from the Infectious Diseases Society of America. Community-acquired pneumonia in adults: Guidelines for management. Clin Infect Dis 1998;26: 811-838.
5. Einarson TR, McGhan WF, Bootman JL. Decision analysis applied to pharmacy practice. Am J Hosp Pharm 1985;42:364-371.
6. Pauker SJ, Kassirer JP. Decision analysis. N Engl J Med 1987;216:250-258.
7. Tenover FC, Hughes JM. The challenges of emerging infectious diseases: Development and spread of multiple-resistant bacterial pathogens. JAMA 1996;275:300-304.
8. Report of the ASM Task Force on Antibiotic Resistance. American Society for Microbiology. Antimicrob Agents Chemother 1995;39(suppl):2-23.
9. Rockefeller University Workshop. Special Report. Multiple-antibiotic resistant pathogenic bacteria. N Engl J Med 1994;330: 1247-1251.
10. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Proceedings of an American Thoracic Society Conference. Am Rev Respir Dis 1993;148:1418-1426.
11. Davis R, Bryson HM. Levofloxacin: A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
12. Cunha BA. Community-acquired pneumonia cost-effective antimicrobial therapy. Postgrad Med 1996;99:109-122.
13. Hayakawa I, Furuhama K, Takayama S, Osada Y. Levofloxacin, a new quinolone antibacterial agent. Arzneim Forsch Drug Res 1992;42:363-364.
14. Nakamori Y, MiyashitaY, Nakatami I, Nakatu K. Levofloxacin: Penetration into sputum and once-daily treatment of respiratory tract infections. Drugs 1995;49(suppl 2):418-419.
15. Shishido H, Furukawa K, Nagai H, Kawakami K, Kono H. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections. Drugs 1995; 49(suppl 2):433-435.
16. Kawai T. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections. Drugs 1995;49(suppl 2):416-417.
17. Sato A, Ogawa H, Iwata M, et al. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections. Drugs 1995;49(suppl 2):428-429.
18. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-1972.
19. ® Red Book 1997. Cardinale V, ed. Montvale, NJ: Medical Economics Company; 1997.
20. White AC Jr, Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: Expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230-239.
21. National Committee for Clinical Laboratory Standards 1998. Performance Standards for Antimicrobial Susceptibility Testing: 8th Informational Supplement. Approved standard document M100-S8. National Committee for Clinical Laboratory Standards, Villanova, PA.
22. AB BIODISK Package Insert, AB BIODISK, Inc., Piscataway, NJ.
23. Reichler MR, Allphin AA, Breiman RF, et al. The spread of multiple resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 1992;166:1346-1353.
24. Nyquist AC, Gonzales R. Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 1998;279:875-877.
25. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-1072.
26. Cohen ML. Epidemiology of drug resistance: Implications for a post-antibiotic era. Science 1992;257:1050-1055.
27. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
28. Musher DM. Streptococcus pneumoniae. In: Mandell GL, ed. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995;1811-1823.
29. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278:901-904.
30. Fine MJ, Smith CA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A metaanalysis. JAMA 1996;275:134-141.
31. Klugman KP, Feldman C. The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia. Infect Dis Clin Pract 1998;7:180-184.
32. Richerson MA, Ambrose PG, Quintiliani R, et al. Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia. Infect Dis Clin Pract 1998;7:227-233.
33. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-119.